194788-10-8

Basic information

• Product Name: 3-HYDROXYCYCLOBUTANECARBOXYLIC ACID
• Synonyms: Cyclobutanecarboxylic acid, 3-hydroxy-;3-HYDROXYCYCLOBUTANECARBOXYLIC ACID;3-Hydroxycyclobutanecarboxylic Acid(WX610009)
• CAS NO: 194788-10-8
• Molecular Formula: C₅H₈O₃
• Molecular Weight: 116.11522
• Mol File: 194788-10-8.mol

Chemical Properties

• Boiling Point: 290.129 °C at 760 mmHg
• Flash Point: 143.5 °C
• Appearance: /
• Density: 1.448 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.565
• Storage Temp.: 2-8°C
• PKA: 4.54±0.40(Predicted)
• CAS DataBase Reference: 3-HYDROXYCYCLOBUTANECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-HYDROXYCYCLOBUTANECARBOXYLIC ACID(194788-10-8)
• EPA Substance Registry System: 3-HYDROXYCYCLOBUTANECARBOXYLIC ACID(194788-10-8)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 194788-10-8(Hazardous Substances Data)

Usage

Uses

Used in Chemical Industry:
3-Hydroxycyclobutanecarboxylic acid is used as an intermediate compound for the synthesis of various chemical products. Its unique cyclic structure and functional groups make it a valuable building block in the creation of complex molecules and materials.
Used in Pharmaceutical Industry:
3-Hydroxycyclobutanecarboxylic acid is used as a key component in the development of pharmaceutical drugs. Its chemical properties allow it to interact with biological targets, potentially leading to the discovery of new therapeutic agents for the treatment of various diseases.
Used in Research and Development:
3-Hydroxycyclobutanecarboxylic acid is used as a research tool in academic and industrial laboratories. Its synthesis and properties are studied to gain insights into the behavior of cyclic organic compounds and to explore new methods for their preparation and modification.

InChI:InChI=1/C5H8O3/c6-4-1-3(2-4)5(7)8/h3-4,6H,1-2H2,(H,7,8)

Upstream product

• 4934-99-0 methylester of 3-hydroxycyclobutane-1-carboxylic acid 
• 480449-99-8 3-hydroxycyclobutylcarboxylic acid benzyl ester 

Downstream Products

• 1558030-49-1 N-(5-((2-(3-hydroxycyclobutanecarboxamido)pyridin-4-yl)oxy)pyridin-2-yl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1365645-63-1 C₂₁H₂₄BrN₅O₃ 
• 480450-01-9 benzyl 3-methoxycyclobutanecarboxylate 

Relevant articles and documents

Synthesis method of cis-3-hydroxycyclobutylcarboxylic acid

The invention belongs to the field of organic synthesis, and discloses a synthesis method of cis-3-hydroxycyclobutylcarboxylic acid. The synthesis method comprises the following steps: performing efficient stereoselective reduction on 3-carbonyl-cyclobutanecarboxylate (C1-C6 alkyl ester) into single cis-3-hydroxy-cyclobutanecarboxylate by using a proper reducing agent, and performing a hydrolysisreaction to finally obtain the single cis-3-hydroxy-cyclobutanecarboxylic acid. By the synthesis method, raw materials are easy to obtain, the reaction condition is mild, the stereoselectivity is good, and the yield is relatively high; in addition, post-treatment and purification are easy to operate, and the synthesis method is suitable for industrial scale-up production.

DIAMINE DERIVATIVES

A compound represented by formula (1):Q1-Q2-To-N(R1) -Q3-N(R2)-T1-Q4 [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Diamine derivatives

A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

DIAMINE DERIVATIVES

A compound represented by the general formula (1):Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.